TUCSON, AZ -- (Marketwired) -- 08/25/14 -- CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that the Company has been invited to present at the National Investment Banking Association's ("NIBA") 132nd Investment Conference to be held in New York on September 15-17, 2014.
NIBA is a national not-for-profit trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8800 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all Initial Public Offerings under $20 million.
NIBA conferences provide a venue for invited companies to share meaningful insight into their business operations, short and long-term growth strategies and industry vision, give its members the opportunity to exchange ideas and information, evaluate presentations made by public and private companies seeking capital or exposure to the investor community.
EVENT AT A GLANCE
Jeffrey Brumfield - Chairman and Chief Executive Officer
Jason Terrell, M.D. - Medical Director
John Coates, Ph.D. - Technical Director of Spectroscopy Products
September 15-17, 2014
The Roosevelt Hotel
45 E. 45th Street
About CDEX Inc.
Headquartered in Tucson, Arizona, CDEX is engaged in pioneering technological advancements in the field of chemical and medication detection and validation for the healthcare and security markets. The Company's proprietary solutions are based on its patented Enhanced Photoemission Spectroscopy technology for substance verification, authentication and identification; and include the ValiMed Medication Validation System product line marketed to healthcare markets worldwide for use in combatting diversion of controlled substances and narcotics, as well as compounded liquid pharmaceuticals to help ensure patient safety, and the ID2 product line marketed to the global security market for use in detecting illegal or illicit drugs in difficult-to-monitor, critical environments. For more information, please visit www.cdex-inc.com.